ArsenalBio

United States
South San Francisco, California, United States, 94080

Company profile

ArsenalBio company profile

ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.

Business identity

Contact email
[email protected]
Phone number
+1 650-240-8844
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Founded
2019-01-01, Year

Headquarters

Postal code
94080
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
4
Total equity funding
$630.8M
Last funding
Series C / $325M / 2024-09-04
Last equity funding
Series C / $325M
Investors
25
Lead investors
1
Founders
3
Articles
26

Founders and investors

Founders

Ken DrazanKole RoybalW. Nicholas Haining

Lead investors

SoftBank Vision Fund

Investors

ARCH Venture PartnersKleiner PerkinsNVenturesOUP (Osage University Partners)Sixth Street